Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | Blood mass-spectrometry for detecting disease progression

Angela Dispenzieri • 1 May 2020
Amyloidosis Rare Diseases

Angela Dispenzieri, MD, of the Mayo Clinic College of Medicine, Rochester, MN, outlines the use of blood mass-spectrometry to detect immunoglobulins in amyloidosis as a measure of disease progression. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).

More from Angela Dispenzieri

Unmet needs in amyloidosis: early diagnosis, treating relapsed disease & progression criteria 1:53
Unmet needs in amyloidosis: early diagnosis, treating relapsed disease & progression criteria
Angela Dispenzieri • 6 Sep 2023
Emerging AL amyloidosis treatments: immunotherapies & targeting amyloid plaque deposits 2:30
Emerging AL amyloidosis treatments: immunotherapies & targeting amyloid plaque deposits
Angela Dispenzieri • 6 Sep 2023
The current SOC in AL amyloidosis: dara-CyBorD & considerations for patients with relapsed disease 1:42
The current SOC in AL amyloidosis: dara-CyBorD & considerations for patients with relapsed disease
Angela Dispenzieri • 6 Sep 2023
Rationale behind the watch and wait strategy in smoldering myeloma 1:57
Rationale behind the watch and wait strategy in smoldering myeloma
Angela Dispenzieri • 6 Sep 2023

Related Videos

Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes 2:03
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes
Gareth Morgan • 7 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals